Methotrexate in atherogenesis and cholesterol metabolism

Cholesterol

Volumn 2011, Issue , 2011, Pages

  Reiss, Allison B ^b   Coomes, Eric ^a   Chan, Edwin S L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

26 HYDROXYCHOLESTEROL; ABC TRANSPORTER A1; ADENOSINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; GAMMA INTERFERON; METHOTREXATE; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; STAT PROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

EID: 79955114904     PISSN: 20901283     EISSN: 20901291     Source Type: Journal    
DOI: 10.1155/2011/503028     Document Type: Review

References (57)

1. Meune C., Touz E., Trinquart L., Allanore Y., High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis Archives of Cardiovascular Diseases 2010 103 4 253 261
2. Feldmann M., Brennan F. M., Maini R. N., Role of cytokines in rheumatoid arthritis Annual Review of Immunology 1996 14 397 440 (Pubitemid 26130190)
3. Tanasescu C., Jurcut C., Jurcut R., Ginghina C., Vascular disease in rheumatoid arthritis: from subclinical lesions to cardiovascular risk European Journal of Internal Medicine 2009 20 4 348 354
4. Furst D. E., Ulrich R. W., Varkey-Altamirano C., Katzung B. G., Masters S. B., Trevor A. J., Nonsteroidal anti-inflammatory drugs, disease modifying antirheumatic drugs, nonopiod analgesics drugs used in gout Basic and Clinical Pharmacology 2009 11th New York, NY, USA McGraw Hill 621 642
5. FitzGerald G. A., Coxibs and cardiovascular disease New England Journal of Medicine 2004 351 17 1709 1711
6. Chan E. S. L., Cronstein B. N., Methotrexatehow does it really work? Nature Reviews Rheumatology 2010 6 3 175 178
7. Castellsague J., Holick C. N., Hoffman C. C., Gimeno V., Stang M. R., Perez-Gutthann S., Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs Pharmacotherapy 2009 29 12 1397 1407
8. Sun S. X., Lee K. Y., Bertram C. T., Goldstein J. L., Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization Current Medical Research and Opinion 2007 23 8 1859 1866 (Pubitemid 47300385)
9. Chan E. S. L., Oliver S. N., Cronstein B. N., Rich R. R., Fleisher T. A., Shearer W. T., Schroeder H. W., Frew A. J., Weyand C. M., Immunomodulating pharmaceuticals Clinical Immunology: Principles and Practice 2008 3rd Philadelphia, Pa, USA Mosby Elsevier 90-1 90-9
10. Westlake S. L., Colebatch A. N., Baird J., Kiely P., Quinn M., Choy E., Ostor A. J. K., Edwards C. J., The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review Rheumatology 2009 49 2 295 307
11. Reiss A., Zhang H., Edelman S., Unraveling coxib atherogenicity: adenosine A2A receptor agonists reverse disruption of cholesterol efflux induced by cyclooxygenase (COX)-2 inhibition Inflammation Research 2006 55 S117 S118
12. Reiss A. B., Anwar F., Chan E. S. L., Anwar K., Disruption of cholesterol efflux by coxib medications and inflammatory processes: link to increased cardiovascular risk Journal of Investigative Medicine 2009 57 6 695 702
13. Reiss A. B., Carsons S. E., Anwar K., Rao S., Edelman S. D., Zhang H., Fernandez P., Cronstein B. N., Chan E. S. L., Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages Arthritis and Rheumatism 2008 58 12 3675 3683
14. Chan E. S. L., Zhang H., Fernandez P., Edelman S. D., Pillinger M. H., Ragolia L., Palaia T., Carsons S., Reiss A. B., Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk Arthritis Research and Therapy 2007 9
15. Ralevic V., Burnstock G., Receptors for purines and pyrimidines Pharmacological Reviews 1998 50 3 413 492 (Pubitemid 28477681)
16. Olah M. E., Stiles G. L., The role of receptor structure in determining adenosine receptor activity Pharmacology and Therapeutics 2000 85 2 55 75 (Pubitemid 30069477)
17. Montesinos M. C., Desai A., Cronstein B. N., Suppression of inflammation by low-dose methotrexate is mediated by adenosine A receptor but not A receptor activation in thioglycollate-induced peritonitis Arthritis Research and Therapy 2006 8 2
18. McPherson J. A., Barringhaus K. G., Bishop G. G., Sanders J. M., Rieger J. M., Hesselbacher S. E., Gimple L. W., Powers E. R., Macdonald T., Sullivan G., Linden J., Sarembock I. J., Adenosine A receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 5 791 796 (Pubitemid 32448770)
19. Borea P. A., Gessi S., Bar-Yehuda S., Fishman P., A adenosine receptor: pharmacology and role in disease Handbook of Experimental Pharmacology 2009 193 297 327
20. Nakav S., Chaimovitz C., Sufaro Y., Lewis E. C., Shaked G., Czeiger D., Zlotnik M., Douvdevani A., Anti-inflammatory preconditioning by agonists of adenosine A1 receptor PLoS One 2008 3 5
21. Ross R., Atherosclerosisan inflammatory disease New England Journal of Medicine 1999 340 2 115 126
22. Libby P., Changing concepts of atherogenesis Journal of Internal Medicine 2000 247 3 349 358 (Pubitemid 30180037)
23. Von Eckardstein A., Nofer J. R., Assmann G., High density lipoproteins and arteriosclerosis role of cholesterol efflux and reverse cholesterol transport Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 1 13 27 (Pubitemid 32061923)
24. Kruth H. S., Macrophage foam cells and atherosclerosis Frontiers in Bioscience 2001 6 D429 D455
25. Ohashi R., Mu H., Wang X., Yao Q., Chen C., Reverse cholesterol transport and cholesterol efflux in atherosclerosis Monthly Journal of the Association of Physicians 2005 98 12 845 856 (Pubitemid 43071450)
26. Oram J. F., Lawn R. M., ABCA1: the gatekeeper for eliminating excess tissue cholesterol Journal of Lipid Research 2001 42 8 1173 1179 (Pubitemid 32744239)
27. Terasaka N., Wang N., Yvan-Charvet L., Tall A. R., High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1 Proceedings of the National Academy of Sciences of the United States of America 2007 104 38 15093 15098 (Pubitemid 47619598)
28. Babiker A., Andersson O., Lund E., Xiu R. J., Deeb S., Reshef A., Leitersdorf E., Diczfalusy U., Bjrkhem I., Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein- mediated reverse cholesterol transport Journal of Biological Chemistry 1997 272 42 26253 26261 (Pubitemid 27458836)
29. Wang X., Rader D. J., Molecular regulation of macrophage reverse cholesterol transport Current Opinion in Cardiology 2007 22 4 368 372 (Pubitemid 46897290)
30. Kolovou G. D., Mikhailidis D. P., Anagnostopoulou K. K., Daskalopoulou S. S., Cokkinos D. V., Tangier disease four decades of research: a reflection of the importance of HDL Current Medicinal Chemistry 2006 13 7 771 782
31. Iatan I., Alrasadi K., Ruel I., Alwaili K., Genest J., Effect of ABCA1 mutations on risk for myocardial infarction Current Atherosclerosis Reports 2008 10 5 413 426
32. Albrecht C., Soumian S., Amey J. S., Sardini A., Higgins C. F., Davies A. H., Gibbs R. G. J., ABCA1 expression in carotid atherosclerotic plaques Stroke 2004 35 12 2801 2806 (Pubitemid 39565174)
33. Lee-Rueckert M., Lappalainen J., Leinonen H., Pihlajamaa T., Jauhiainen M., Kovanen P. T., Acidic extracellular environments strongly impair ABCA1-mediated cholesterol efflux from human macrophage foam cells Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 9 1766 1772
34. Naghavi M., John R., Naguib S., Siadaty M. S., Grasu R., Kurian K. C., Van Winkle W. B., Soller B., Litovsky S., Madjid M., Willerson J. T., Casscells W., pH heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque Atherosclerosis 2002 164 1 27 35 (Pubitemid 34765634)
35. Reiss A. B., Glass A. D., Atherosclerosis: immune and inflammatory aspects Journal of Investigative Medicine 2006 54 3 123 131
36. Olkkonen V. M., Lehto M., Oxysterols and oxysterol binding proteins: role in lipid metabolism and atherosclerosis Annals of Medicine 2004 36 8 562 572 (Pubitemid 40051433)
37. Bjrkhem I., Diczfalusy U., Oxysterols: friends, foes, or just fellow passengers? Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 5 734 742
38. Bjorkhem I., Andersson O., Diczfalusy U., Sevastik B., Xiu R. J., Duan C., Lund E., Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages Proceedings of the National Academy of Sciences of the United States of America 1994 91 18 8592 8596 (Pubitemid 24273710)
39. Babiker A., Dzeletovic S., Wiklund B., Pettersson N., Salonen J., Nyyssnen K., Eriksson M., Diczfalusy U., Bjrkhem I., Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid Scandinavian Journal of Clinical and Laboratory Investigation 2005 65 5 365 376 (Pubitemid 41134085)
40. Fu X., Menke J. G., Chen Y., Zhou G., MacNaul K. L., Wright S. D., Sparrow C. P., Lund E. G., 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells Journal of Biological Chemistry 2001 276 42 38378 38387
41. Murthy S., Born E., Mathur S. N., Field F. J., LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells Journal of Lipid Research 2002 43 7 1054 1064 (Pubitemid 34760876)
42. Edwards P. A., Kennedy M. A., Mak P. A., LXRs; Oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis Vascular Pharmacology 2002 38 4 249 256 (Pubitemid 36398270)
43. Reiss A. B., Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus Current Rheumatology Reports 2009 11 4 255 260
44. George J., Harats D., Gilburd B., Levy Y., Langevitz P., Shoenfeld Y., Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis Lupus 1999 8 3 220 226 (Pubitemid 29186841)
45. Virella G., Lopes-Virella M. F., Atherogenesis and the humoral immune response to modified lipoproteins Atherosclerosis 2008 200 2 239 246
46. Reiss A. B., Rahman M. M., Chan E. S. L., Montesinos M. C., Awadallah N. W., Cronstein B. N., Adenosine A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages Journal of Leukocyte Biology 2004 76 3 727 734 (Pubitemid 39129107)
47. Reiss A. B., Awadallah N. W., Malhotra S., Montesinos M. C., Chan E. S. L., Javitt N. B., Cronstein B. N., Immune complexes and IFN- decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages Journal of Lipid Research 2001 42 11 1913 1922 (Pubitemid 33116723)
48. Hao X. R., Cao D. L., Hu Y. W., Li X. X., Liu X. H., Xiao J., Liao D. F., Xiang J., Tang C. K., IFN- down-regulates ABCA1 expression by inhibiting LXR in a JAK/STAT signaling pathway-dependent manner Atherosclerosis 2009 203 2 417 428
49. Barnholt K. E., Kota R. S., Aung H. H., Rutledge J. C., Adenosine blocks IFN- -induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation Journal of Immunology 2009 183 10 6767 6777
50. McLaren J. E., Ramji D. P., Interferon gamma: a master regulator of atherosclerosis Cytokine and Growth Factor Reviews 2009 20 2 125 135
51. Nair J. S., DaFonseca C. J., Tjernberg A., Sun W., Darnell J. E., Chait B. T., Zhang J. J., Requirement of Ca2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN- Proceedings of the National Academy of Sciences of the United States of America 2002 99 9 5971 5976 (Pubitemid 34493249)
52. Landew R. B. M., Van Den Borne B. E. E. M., Breedveld F. C., Dijkmans B. A. C., Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity Lancet 2000 355 9215 1616 1617 (Pubitemid 30240511)
53. Lynge J., Schulte G., Nordsborg N., Fredholm B. B., Hellsten Y., Adenosine A receptors modulate cAMP levels and induce CREB but not ERK1/2 and p38 phosphorylation in rat skeletal muscle cells Biochemical and Biophysical Research Communications 2003 307 1 180 187 (Pubitemid 36808551)
54. Bingham T. C., Fisher E. A., Parathath S., Reiss A. B., Chan E. S., Cronstein B. N., A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux Journal of Leukocyte Biology 2010 87 4 683 690
55. Bos J. L., Epac: a new cAMP target and new avenues in cAMP research Nature Reviews Molecular Cell Biology 2003 4 9 733 738 (Pubitemid 37082188)
56. Martin L., Pingle S. C., Hallam D. M., Rybak L. P., Ramkumar V., Activation of the adenosine A receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor- release by reducing calcium-dependent activation of nuclear factor- B and extracellular signal-regulated kinase 1/2 Journal of Pharmacology and Experimental Therapeutics 2006 316 1 71 78 (Pubitemid 41832582)
57. Ridker P. M., Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) Journal of Thrombosis and Haemostasis 2009 7 1 332 339